Evidence map›Paper›PMID 37780565›Full record

ArticleFrontiers in medicine2023

Treatment of metastatic squamous cell carcinoma arising in sacrococcygeal pilonidal sinus: a case report series.

Ainara Soria Rivas, Sonia Bea-Ardebol, Elena Vida Navas, Óscar M Muñoz-Arrones, Luis Jacobo Cabañas-Montero, Antonio Mena-Mateos, Fernando López-Campos, Sara Corral Moreno, Israel Pérez-Muñoz, Fausto González Lizan and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Ainara Soria RivasMedical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Sonia Bea-ArdebolDermatology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Elena Vida NavasMedical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Óscar M Muñoz-ArronesDermatology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Luis Jacobo Cabañas-MonteroSurgery Department, Ramon y Cajal University Hospital, Madrid, Spain.
Antonio Mena-MateosSurgery Department, Ramon y Cajal University Hospital, Madrid, Spain.
Fernando López-CamposRadiation Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Sara Corral MorenoSurgery Department, Ramon y Cajal University Hospital, Madrid, Spain.
Israel Pérez-MuñozOrthopedics and Orthopedic Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain.
Fausto González LizanOrthopedics and Orthopedic Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain.
María Sanz PascualOrthopedics and Orthopedic Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain.
Juan Jose Serrano DomingoMedical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
Instituto Cajal · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Squamous cell carcinoma (SCC) arising in a sacrococcygeal pilonidal sinus is rare, with cases of metastatic disease being even rarer. Among published cases, almost none have reported on systemic treatment. Objective: This disease has a poorer prognosis than other forms of cutaneous SCC; therefore, our objective is to shed some light on the treatment of metastatic disease. Methods: We present a series of nine cases treated at a single center, four of whom received systemic treatment. Additionally, other previously reported cases of metastatic disease are included in an attempt to draw stronger conclusions. Results: Four patients were treated under several treatment regimens, with a median progression-free survival of only 2 months and two instances of partial response (18%). The best result was achieved with cemiplimab. Across all the cases, there was a trend toward a benefit of the use of systemic treatment (HR 0.41, 95% CI 0.15-1.12, Limitations: Limitations include the significant lack of information on previously published cases and the extremely heterogeneous nature of the existing information. Conclusion: The initial systemic treatment should be an anti-PD-1, as with other SCCs. After progression on anti-PD-1, there is no strong evidence to support the recommendation of a specific treatment or sequence: options include cetuximab and/or chemotherapy (platinum, paclitaxel, 5-fluorouracyl).

Indexed as

anti-PD-1case reportchemotherapymetastaticpilonidal sinussquamous cell carcinoma

Identifiers

PMID37780565
PMCPMC10534040
OpenAlexW4386698021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.